Cerebrospinal fluid (CSF), positron emission tomography (PET) and magnetic resonance imaging (MRI) serve as three important tools to track biological changes in AD. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) provides the infrastructure for investigators to examine the longitudinal patterns of CSF, PET and MRI biomarkers at different cognitive stages. We delineated the biomarker changes over time in relation to cognitive decline in ADNI and found that the trajectories support a hypothetical sequence of AD pathology, suggesting that biomarker prediction for cognitive change is stage dependent.
Cognitive reserve has been proposed to account for the discordance between cognitive performance and AD pathology. The long held viewpoint is that cognitive reserve affects the clinical expression but has no direct effect on AD pathology. This viewpoint was re-examined in our study. The results showed that higher cognitive reserve indexed by education and other proxies was associated with slower rates of AD pathological deterioration, particularly among cognitively normal elderly people. These findings suggest that the pathological course of AD can be modified by cognitive reserve.
講者介紹
羅彥宇 醫師，美國加州大學柏克萊校區流行病學博士，現職慈濟醫院神經內科主治醫師
專 長
神經退化疾病、巴金森病及其他動作障礙
學 歷
慈濟大學醫學系
美國史丹佛大學臨床流行病學碩士
美國加州大學柏克萊校區流行病學博士
經 歷
海軍中訓軍艦少尉醫官
花蓮慈濟醫院神經內科住院醫師
美國巴金森研究院暨臨床中心神經流行病學研究醫師
獎 項
美國阿茲海默協會2011 年輕科學家榮譽獎